Download PDF
Am J Perinatol 1998; 15(5): 295-297
DOI: 10.1055/s-2007-993946
ORIGINAL ARTICLE

© 1998 by Thieme Medical Publishers, Inc.

Successful Fetal Outcome After Exposure to Idarubicin and Cytosine-Arabinoside During the Second Trimester of Pregnancy-A Case Report

Hedi L. Claahsen1 , Ben A. Semmekrot1 , Pieter W. J. van Dongen2 , Vera Mattijssen3
  • 1Department of Neonatology, University Hospital “St. Radboud,” Nijmegen, The Netherlands
  • 2Department of Obstetrics and Gynaecology, University Hospital “St. Radboud,” Nijmegen, The Netherlands
  • 3Department of Hematology, University Hospital “St. Radboud,” Nijmegen, The Netherlands
Further Information

Publication History

Publication Date:
04 March 2008 (online)

    Permissions and Reprints

ABSTRACT

Chemotherapeutic agents administered to the mother during pregnancy may severely jeopardize the fetus. We describe a newborn girl who had been exposed to idarubicin and cytosine-arabinoside during the second and third trimesters of pregnancy due to treatment of newly diagnosed acute myeloid leukemia in the mother. The child had no structural congenital abnormalities. Adverse effects observed were prematurity, growth retardation, mildly disturbed transaminases and erythroblastosis, all of which were self-limiting with no permanent sequelae.

Keywords

Pregnancy - newborn - chemotherapeutic agents

      >